


[¹⁸F]3-Fluoro-5-[(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile

[¹⁸F]F-MTEB

The MICAD Research Team

Created: July 12, 2006; Updated: July 24, 2006.

Chemical name:	[¹⁸ F]3-Fluoro-5-[(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile	
Abbreviated name:	[¹⁸ F]F-MTEB	
Synonym:		
Agent Category:	Compound	
Target:	Metabotropic glutamate subtype 5 (mGlu5) receptor	
Target Category:	Receptor binding	
Method of detection:	PET	
Source of signal:	¹⁸ F	
Activation:	No	
Studies:	<ul style="list-style-type: none">• <i>In vitro</i>• Rodents• Non-human primates	

Click on the above structure for additional information in [PubChem](#).

Background

[[PubMed](#)]

NLM Citation: The MICAD Research Team. [¹⁸F]3-Fluoro-5-[(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile. 2006 Jul 12 [Updated 2006 Jul 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.

[¹⁸F]3-Fluoro-5-[(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile ([¹⁸F]F-MTEB) is a radioligand developed for positron emission tomography (PET) imaging of metabotropic glutamate receptor subtype 5 (mGlu5) in the central nervous system (CNS) (1).

Glutamate is a major excitatory neurotransmitter at CNS synapses. Many neuroanatomical CNS projection pathways contain glutamatergic neurons (2). Glutamate produces its excitatory effects by acting on cell-surface ionotropic glutamate or metabotropic glutamate (mGlu) receptors (3). The mGlu receptors are G-protein-coupled receptors, and the eight mGlu receptor subtypes are further subdivided into groups I, II, and III. The group I receptors include mGlu1 and mGlu5, and they are found mostly in postsynaptic locations. The mGlu5 receptors are found with high to moderate density in the frontal cortex, caudate, putamen, nucleus accumbens, olfactory tubercle, hippocampus, and dorsal horn of the spinal cord, whereas the density in the cerebellum is low. These receptors are coupled to phospholipase C and up- or down-regulate neuronal excitability. They have been implicated in a variety of diseases in the CNS, including anxiety, depression, schizophrenia, Parkinson's disease, and drug addiction or withdrawal. These receptors are also involved in the modulation of various pain states. They thus are attractive targets for therapeutic drug development.

PET and single-photon emission tomography of radioligands targeting mGlu5 receptors can visualize and study the CNS mGlu5 receptors in normal and pathologic states. Some mGlu5 antagonists have been successfully labeled, but their *in vivo* visualization has been hampered by high lipophilicity, unfavorable brain uptake kinetics, or a high metabolism (4, 5). 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) have been identified as potent and highly selective noncompetitive antagonists for mGlu5 receptors. Using the structure of MTEP as a template, Hamill et al. (1) and Patel et al (5). designed several MTEP analogs as PET radiotracers, and [¹⁸F]F-MTEB was one of the compounds that showed high affinity for mGlu5 receptors with moderate lipophilicity.

Synthesis

[PubMed]

Hamill et al. (1) reported the radiosynthesis of [¹⁸F]F-MTEB, from the aryl chloride via a nucleophilic aromatic substitution reaction. The precursor was obtained commercially. In the preparation, Kryptofix222 was added to the aqueous [¹⁸F]F⁻ solution in a microwave cavity. The fluoride was dried under argon gas flow by use of microwave pulses (~45 W). The precursor, in dimethyl sulfoxide, was added to the microwave vial. The reaction mixture was then pulsed with the microwave 5 times at 15 s/pulse and a 30-s pause between pulses. After cooling for 1 min, the reaction was diluted with water and then purified by high-performance liquid chromatography. This procedure gave 259 MBq(7 mCi) of [¹⁸F]F-MTEB with a specific activity ($n = 2$) of 49.9 ± 17.4 TBq ($1,348 \pm 469$ Ci)/mmol, and a radiochemical purity >98%. The time of synthesis was ~ 35 min with a radiochemical yield of $\sim 4 \pm 0.9\%$ ($n = 10$) at the end of synthesis (uncorrected).

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

Patel et al. (5) used *in vitro* rat brain preparations to determine the *in vitro* mGlu5 binding parameters of unlabeled F-MTEB. [³H]MethoxyPyEP, a mGlu5 antagonist, was used in the equilibrium competition studies. The B_{max} for the rat frontal cortex was reported to be 64.7 fmol/mg of tissue (6). The K_i of F-MTEB determined from rat cortical membranes was 0.08 ± 0.02 (*n* = 3) nM, and the partition coefficient (log P) was 3.2 (octanol/buffer, pH 7.4). Hamill et al. (1) reported that the inhibitory concentration (IC₅₀; human mGlu5 Ca²⁺ flux assay) was 1.45 ± 0.5 nM (*n* = 5).

Using a rapid *in vitro* binding assay they had developed, Patel et al. (7) determined the *in vitro* regional distribution of [¹⁸F]F-MTEB in rat and rhesus monkey brain sections. Rat and rhesus brain sections were incubated with [¹⁸F]F-MTEB and assayed for 20 min, using a no-wash protocol. The percentages of specific binding (*n* ≥ 2) at 20 min were 69 ± 6.5 and 65 ± 11 for rat and rhesus caudate sections, respectively.

In vitro autoradiographic studies (1) of [¹⁸F]F-MTEB were carried out in rhesus monkey brain slices (from a single monkey). Good specific to nonspecific regioselective labeling with reasonable binding was found in the cortex, caudate, putamen, amygdale, hippocampus, and most thalamic nuclei. The cerebellar layers showed lower receptor density. In a saturation binding experiment, the B_{max} values for mGlu5 were determined to be 63 and 24 nM in the rhesus caudate and cerebellum, respectively. *In vitro* metabolism of [¹⁸F]F-MTEB was studied by incubation of the radiotracer with human and monkey liver microsomes. Liquid chromatography-tandem mass spectrometry showed that the radiotracer was metabolized slowly by human microsomes. Approximately 60% of the intact compound remained at the end of 30 min. In contrast, the compound was metabolized much faster by monkey liver microsomes: only 2% of the intact compound remained at the end of 30 min.

Animal Studies

Rodents

[PubMed]

Patel et al. (5) assessed the *in vivo* distribution of [¹⁸F]F-MTEB via micro-PET imaging in the rat brain. The rat received ~18.5 MBq (0.5 mCi) of [¹⁸F]F-MTEB (specific activity ≈ 74 TBq (2,000 Ci)/mmol) by intravenous injection. [¹⁸F]F-MTEB exhibited the highest uptake (mean normalized activity unit (NAU) of corpus striatum (CS) = 0.64) than other ligands (CS NAUs = 0.19 -0.47) evaluated in the same study and an excellent *in vivo* specific signal-to-noise ratio. The specific binding and signal-to-noise ratio were reasonably well maintained over 90 min. The corpus striatum/cerebellum ratio was 7. [¹⁸F]F-MTEB radioactivity specific binding was blocked by a dose of 10 mg/kg MPEP. The blocking dose reduced [¹⁸F]F-MTEB radioactivity localization in the caudate and

cortex to the same level of cerebellum. The dose-inhibition curve estimated the ID₅₀ dose of MPEP to be ~1 mg/kg.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

PET imaging with [¹⁸F]F-MTEB was carried out in three rhesus monkeys (1). Each monkey received ~185 MBq (5 mCi) of the radiotracer. PET showed rapid brain uptake of [¹⁸F]F-MTEB radioactivity and substantial mGlu5-specific signals in all gray matter regions, including the cerebellum. The wash-out from the brain was relatively slow and thus produced large, long-lived specific signals. The nonspecific signal was determined from the radioactivity in the white matter with a blocking dose of 1 mg/kg MTEP. The total/nonspecific signal ratio at 90 min was 8.4. Coregistered magnetic resonance imaging/PET imaging confirmed that the radioactivity uptake was in the striatum, cortical regions, and cerebellum. The highest concentration of radioactivity was observed in the striatum with ~3.1 standard uptake value (SUV) units at ~65 min. Radioactivity uptake was lower in the frontal cortex and even lower in the cerebellum. These uptakes were blocked by MTEP pretreatment. The distribution of radioactivity seen in PET imaging was consistent with the *in vitro* autoradiography pattern.

Human Studies

[PubMed]

No publication is currently available.

References

1. Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, Cosford ND, Roppe J, Kamenecka T, Patel S, Gibson RE, Sanabria S, Riffel K, Eng W, King C, Yang X, Green MD, O'Malley SS, Hargreaves R, Burns HD. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. *Synapse*. 2005;56(4):205–216. PubMed PMID: 15803497.
2. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. *Neuropharmacology*. 1995;34(1):1–26. PubMed PMID: 7623957.
3. Slassi A, Isaac M, Edwards L, Minidis A, Wensbo D, Mattsson J, Nilsson K, Raboisson P, McLeod D, Stormann TM, Hammerland LG, Johnson E. Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. *Curr Top Med Chem*. 2005;5(9):897–911. PubMed PMID: 16178734.

4. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, Auberson YP, Gasparini F, Schubiger PA. Radiosynthesis and Preclinical Evaluation of ¹¹C-ABP688 as a Probe for Imaging the Metabotropic Glutamate Receptor Subtype 5. *J Nucl Med.* 2006;47(4):698–705. PubMed PMID: 16595505.
5. Patel S, Ndubizu O, Hamill T, Chaudhary A, Burns HD, Hargreaves R, Gibson RE. Screening cascade and development of potential Positron Emission Tomography radiotracers for mGluR5: in vitro and in vivo characterization. *Mol Imaging Biol.* 2005;7(4):314–323. PubMed PMID: 16080024.
6. Patel S, Krause SM, Hamill T, Chaudhary A, Burns DH, Gibson RA. In vitro characterization of [³H]MethoxyPyEP, an mGluR5 selective radioligand. *Life Sci.* 2003;73(3):371–379. PubMed PMID: 12757844.
7. Patel S, Hamill T, Hostetler E, Burns HD, Gibson RE. An in vitro assay for predicting successful imaging radiotracers. *Mol Imaging Biol.* 2003;5(2):65–71. PubMed PMID: 14499146.